Redhill Biopharma Announced The Renewal Of Its Contract With Medi-Cal, California's Medicaid Healthcare Program, To Maintain Talicia's First-line Position On Medi-Cal Fee-For-Service Contract Drug List With No Prior Authorization And A $0 Copay, Effective October 1
Portfolio Pulse from Benzinga Newsdesk
Redhill Biopharma has renewed its contract with Medi-Cal, California's Medicaid program, ensuring Talicia remains a first-line treatment with no prior authorization and a $0 copay, effective October 1.
October 01, 2024 | 11:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Redhill Biopharma has successfully renewed its contract with Medi-Cal, ensuring Talicia remains a first-line treatment option with no prior authorization and a $0 copay, starting October 1.
The renewal of the contract with Medi-Cal is significant for Redhill Biopharma as it ensures continued access to a large patient base in California without barriers like prior authorization. This could lead to increased sales and revenue for Talicia, positively impacting RDHL's stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90